SUPPLEMENT
Q4 2021 — Financial disclosures
Q4 2021PDF · 10 pages1.1 MB
Merck & Co., Inc. Financial Highlights Package Fourth Quarter 2021 Table of Contents Table 1: GAAP P&L....................................................................................1 Table 1a: GAAP P&L – Current Year and Prior Year by Quarter.................2 Table 2a: GAAP to Non-GAAP Reconciliation 4Q21 and Dec YTD 21........3 Table 2b: GAAP to Non-GAAP Reconciliation 4Q20 and Dec YTD 20........4 Table 3: Sales - Current Year and Prior Year by Quarter..........................5 Table 3a: Sales – U.S. / Ex- U.S. 4Q21.......................................................6 Table 3b: Sales – U.S. / Ex- U.S. Dec YTD 21 ............................................7 Table 3c: Sales – Pharmaceutical Geographic Split....................................8 Table 4: Other (Income) Expense..............................................................9 -- 1 of 10 -- Sales 13,521 $ 10,948 $ 24% 48,704 $ 41,518 $ 17% Costs, Expenses and Other Cost of sales 3,873 5,029 -23% 13,626 13,618 0% Selling, general and administrative 2,830 2,619 8% 9,634 8,955 8% Research and development 3,068 5,788 -47% 12,245 13,397 -9% Restructuring costs (1) 174 310 -44% 661 575 15% Other (income) expense, net (333) (253) 32% (1,341) (890) 51% Income (Loss) from Continuing Operations Before Taxes 3,909 (2,545) * 13,879 5,863 * Income Tax Provision 85 69 1,521 1,340 Net Income (Loss) from Continuing Operations 3,824 (2,614) * 12,358 4,523 * Less: Net Income Attributable to Noncontrolling Interests 4 3 13 4 Net Income (Loss) from Continuing Operations Attributable to Merck & Co., Inc. 3,820 $ (2,617) $ * 12,345 $ 4,519 $ * (Loss) Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests (62) $ 523 $ * 704 $ 2,548 $ -72% Net Income (Loss) Attributable to Merck & Co., Inc. 3,758 $ (2,094) $ * 13,049 $ 7,067 $ 85% Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders: Income (Loss) from Continuing Operations 1.51 $ (1.03) $ * 4.88 $ 1.79 $ * (Loss) Income from Discontinued Operations (0.02) $ 0.21 $ * 0.28 $ 1.01 $ -72% Net Income (Loss) 1.49 $ (0.83) $ * 5.16 $ 2.79 $ 85% Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: Income (Loss) from Continuing Operations 1.51 $ (1.03) $ * 4.86 $ 1.78 $ * (Loss) Income from Discontinued Operations (0.02) $ 0.21 $ * 0.28 $ 1.00 $ -72% Net Income (Loss) 1.48 $ (0.83) $ * 5.14 $ 2.78 $ 85% Average Shares Outstanding 2,527 2,530 2,530 2,530 Average Shares Outstanding Assuming Dilution (2) 2,535 2,530 2,538 2,541 Tax Rate from Continuing Operations 2.2% -2.7% 11.0% 22.9% * 100% or greater (1) Represents separation and other related costs associated with restructuring activities under the company's formal restructuring programs. (2) Because the company recorded a net loss in the fourth quarter of 2020, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. Income from discontinued operations was also computed using average common shares outstanding. GAAP % Change GAAP % Change 4Q21 4Q20 Full Year 2021 Full Year 2020 On June 2, 2021, Merck completed the spinoff of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to company shareholders. The historical results of the women’s health, biosimilars and established brands businesses that were contributed to Organon in the spin-off are excluded from sales and expenses below and reflected as discontinued operations in the company’s Consolidated Statements of Income provided below. MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 1 1 -- 2 of 10 -- Sales 10,627 $ 11,402 $ 13,154 $ 13,521 $ 48,704 $ 10,288 $ 9,353 $ 10,929 $ 10,948 $ 41,518 $ 24% 17% Costs, Expenses and Other Cost of sales 3,199 3,104 3,450 3,873 13,626 2,829 2,747 3,013 5,029 13,618 -23% 0% Selling, general and administrative 2,187 2,281 2,336 2,830 9,634 2,191 2,085 2,060 2,619 8,955 8% 8% Research and development 2,412 4,321 2,445 3,068 12,245 2,175 2,085 3,349 5,788 13,397 -47% -9% Restructuring costs 297 82 107 174 661 70 82 113 310 575 -44% 15% Other (income) expense, net (455) (103) (450) (333) (1,341) 62 (387) (312) (253) (890) 32% 51% Income (Loss) from Continuing Operations Before Taxes 2,987 1,717 5,266 3,909 13,879 2,961 2,741 2,706 (2,545) 5,863 * * Income Tax Provision 238 503 695 85 1,521 495 396 380 69 1,340 Net Income (Loss) from Continuing Operations 2,749 1,214 4,571 3,824 12,358 2,466 2,345 2,326 (2,614) 4,523 * * Less: Net Income (Loss) Attributable to Noncontrolling Interests 4 1 4 4 13 (5) 4 2 3 4 Net Income (Loss) from Continuing Operations Attributable to Merck & Co., Inc. 2,745 1,213 4,567 3,820 12,345 2,471 2,341 2,324 (2,617) 4,519 * * Income (Loss) from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests 434 332 - (62) 704 748 661 617 523 2,548 * -72% Net Income (Loss) Attributable to Merck & Co., Inc. 3,179 $ 1,545 $ 4,567 $ 3,758 $ 13,049 $ 3,219 $ 3,002 $ 2,941 $ (2,094) $ 7,067 $ * 85% Basic Earnings (Loss) per Common Share Attributable to Merck & Co., Inc. Common Shareholders: Income (Loss) from Continuing Operations 1.08 $ 0.48 $ 1.81 $ 1.51 $ 4.88 $ 0.98 $ 0.93 $ 0.92 $ (1.03) $ 1.79 $ * * Income (Loss) from Discontinued Operations 0.17 0.13 - (0.02) 0.28 0.30 0.26 0.24 0.21 1.01 * -72% Net Income (Loss) 1.26 $ 0.61 $ 1.81 $ 1.49 $ 5.16 $ 1.27 $ 1.19 $ 1.16 $ (0.83) $ 2.79 $ * 85% Earnings (Loss) per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders: Income (Loss) from Continuing Operations 1.08 $ 0.48 $ 1.80 $ 1.51 $ 4.86 $ 0.97 $ 0.92 $ 0.92 $ (1.03) $ 1.78 $ * * Income (Loss) from Discontinued Operations 0.17 0.13 - (0.02) 0.28 0.29 0.26 0.24 0.21 1.00 * -72% Net Income (Loss) 1.25 $ 0.61 $ 1.80 $ 1.48 $ 5.14 $ 1.26 $ 1.18 $ 1.16 $ (0.83) $ 2.78 $ * 85% Average Shares Outstanding 2,531 2,533 2,530 2,527 2,530 2,533 2,527 2,529 2,530 2,530 Average Shares Outstanding Assuming Dilution (1) 2,541 2,540 2,536 2,535 2,538 2,547 2,536 2,538 2,530 2,541 Tax Rate from Continuing Operations 8.0% 29.3% 13.2% 2.2% 11.0% 16.7% 14.4% 14.0% -2.7% 22.9% * 100% or greater Sum of quarterly amounts may not equal year-to-date amounts due to rounding. % Change 4Q Full Year (1) Because the company recorded a net loss in the fourth quarter of 2020, no potential dilutive common shares were used in the computation of loss per common share assuming dilution as the effect would have been anti-dilutive. Income from discontinued operations was also computed using average common shares outstanding. 2021 2Q 3Q 4Q Full Year 1Q 1Q 2Q 3Q 4Q Full Year 2020 Table 1a MERCK & CO., INC. CONSOLIDATED STATEMENT OF INCOME - GAAP (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) 2 -- 3 of 10 -- Fourth Quarter Cost of sales 3,873 $ 419 47 (4) 462 3,411 $ Selling, general and administrative 2,830 226 10 236 2,594 Research and development 3,068 397 7 (17) 387 2,681 Restructuring costs 174 174 174 - Other (income) expense, net (333) (3) (381) (384) 51 Income From Continuing Operations Before Taxes 3,909 (1,039) (238) 381 21 (875) 4,784 Income Tax Provision (Benefit) 85 (163) (5) (39) (5) 84 (5) (2) (5) (120) 205 Net Income from Continuing Operations 3,824 (876) (199) 297 23 (755) 4,579 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 3,820 (876) (199) 297 23 (755) 4,575 Earnings per Common Share Assuming Dilution from Continuing Operations 1.51 $ (0.34) (0.08) 0.12 0.01 (0.29) 1.80 $ Tax Rate 2.2% 4.3% Full Year Cost of sales 13,626 $ 1,607 160 221 (3) 1,988 11,638 $ Selling, general and administrative 9,634 322 19 341 9,293 Research and development 12,245 479 28 1,661 (4) 2,168 10,077 Restructuring costs 661 661 661 - Other (income) expense, net (1,341) 76 (1,884) (1,808) 467 Income From Continuing Operations Before Taxes 13,879 (2,484) (868) 1,884 (1,882) (3,350) 17,229 Income Tax Provision (Benefit) 1,521 (446) (5) (121) (5) 415 (5) (261) (5) (413) 1,934 Net Income from Continuing Operations 12,358 (2,038) (747) 1,469 (1,621) (2,937) 15,295 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 12,345 (2,038) (747) 1,469 (1,621) (2,937) 15,282 Earnings per Common Share Assuming Dilution from Continuing Operations 4.86 $ (0.80) (0.30) 0.58 (0.64) (1.16) 6.02 $ Tax Rate 11.0% 11.2% Only the line items that are affected by non-GAAP adjustments are shown. (5) Represent the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Certain other items for the full year also includes a $207 million net tax benefit related to the settlement of certain federal income tax matters. Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect acquisition and divestiture-related costs, including $169 million of transaction costs related to Acceleron. Amounts included in research and development expenses primarily reflect a $275 million in-process research and development (IPR&D) impairment charge related to the ArQule acquisition, $105 million of Acceleron transaction costs, and expenses for the amortization of intangible assets. Amounts included in other (income) expense, net, for the fourth quarter and full year primarily reflect an increase in the estimated fair value measurement of liabilities for contingent consideration, partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint venture. Additionally, the full year includes a loss on a forward exchange contract entered into in conjunction with the Organon spin-off. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (3) Reflects charges for the discontinuation of COVID-19 development programs. (4) Amount includes a $1.7 billion charge for the acquisition of Pandion Therapeutics, Inc. and a $43 million reduction in expense related to measurement period adjustments for the 2020 VelosBio Inc. acquisition. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items Adjustment Subtotal The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are excluded from the financial information provided below. MERCK & CO., INC. FOURTH QUARTER AND FULL YEAR 2021 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2a 3 -- 4 of 10 -- Fourth Quarter Cost of sales 5,029 $ 1,986 44 260 (5) 2,290 2,739 $ Selling, general and administrative 2,619 42 10 52 2,567 Research and development 5,788 16 16 3,161 (3) 3,193 2,595 Restructuring costs 310 310 310 - Other (income) expense, net (253) (2) (348) (3) (353) 100 (Loss) Income From Continuing Operations Before Taxes (2,545) (2,042) (380) 348 (3,418) (5,492) 2,947 Income Tax Provision (Benefit) 69 (378) (4) (21) (4) 77 (4) (61) (4) (383) 452 Net (Loss) Income from Continuing Operations (2,614) (1,664) (359) 271 (3,357) (5,109) 2,495 Net (Loss) Income from Continuing Operations Attributable to Merck & Co., Inc. (2,617) (1,664) (359) 271 (3,357) (5,109) 2,492 (Loss) Earnings per Common Share Assuming Dilution from Continuing Operations (1.03) $ (0.66) (0.14) 0.11 (1.32) (2.01) 0.98 $ Tax Rate -2.7% 15.3% Full Year Cost of sales 13,618 $ 3,355 175 260 (5) 3,790 9,828 $ Selling, general and administrative 8,955 225 47 272 8,683 Research and development 13,397 12 83 4,243 (3) 4,338 9,059 Restructuring costs 575 575 575 - Other (income) expense, net (890) 50 (1,292) (20) (1,262) 372 Income From Continuing Operations Before Taxes 5,863 (3,642) (880) 1,292 (4,483) (7,713) 13,576 Income Tax Provision (Benefit) 1,340 (627) (4) (80) (4) 284 (4) (303) (4) (726) 2,066 Net Income from Continuing Operations 4,523 (3,015) (800) 1,008 (4,180) (6,987) 11,510 Net Income from Continuing Operations Attributable to Merck & Co., Inc. 4,519 (3,015) (800) 1,008 (4,180) (6,987) 11,506 Earnings per Common Share Assuming Dilution from Continuing Operations 1.78 $ (1.19) (0.31) 0.40 (1.65) (2.75) 4.53 $ Tax Rate 22.9% 15.2% Only the line items that are affected by non-GAAP adjustments are shown. The table below reflects a reconciliation of GAAP to non-GAAP financial information on a continuing operations basis. As Organon results are reflected within discontinued operations, they are excluded from the financial information provided below. MERCK & CO., INC. FOURTH QUARTER AND FULL YEAR 2020 GAAP TO NON-GAAP RECONCILIATION - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES) (UNAUDITED) Table 2b (5) Represents charges for the discontinuation of COVID-19 development programs. Non-GAAP Merck is providing certain non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s results as it permits investors to understand how management assesses performance. Management uses these measures internally for planning and forecasting purposes and to measure the performance of the company along with other metrics. In addition, senior management’s annual compensation is derived in part using non-GAAP pretax income. This information should be considered in addition to, but not as a substitute for or superior to, information prepared in accordance with GAAP. (1) Amounts included in cost of sales primarily reflect a $1.6 billion intangible asset impairment charge related to ZERBAXA and expenses for the amortization of intangible assets. Amounts included in selling, general and administrative expenses reflect acquisition and divestiture-related costs, including $95 million of transaction costs related to the acquisition of Arqule, Inc. for the full year. Amounts included in other (income) expense, net, primarily reflect costs related to increases in the estimated fair value measurement of liabilities for contingent consideration, partially offset by royalty income related to the termination of the Sanofi-Pasteur MSD joint venture. (2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to activities under the company's formal restructuring programs. (4) Represent the estimated tax impacts on the reconciling items based on applying the statutory rate of the originating territory of the non-GAAP adjustments. Acquisition and divestiture-related costs also includes a tax cost of $67 million, representing an adjustment to the tax benefits recorded in conjunction with the 2015 Cubist Pharmaceuticals, Inc. acquisition. GAAP Acquisition and Divestiture- Related Costs (1) Restructuring Costs (2) (Income) Loss from Investments in Equity Securities Certain Other Items Adjustment Subtotal (3) Amounts for the fourth quarter and full year primarily include charges of $2.7 billion for the acquisition of VelosBio Inc., $462 million for the acquisition of OncoImmune and $45 million for the discontinuation of COVID-19 development programs. Additionally, the full year includes $1.1 billion of charges for upfront payments related to license and collaboration agreements. 4 -- 5 of 10 -- 1Q 2Q 3Q 4Q Full Year 1Q 2Q 3Q 4Q Full Year Nom % Ex-Exch % Nom % Ex-Exch % TOTAL SALES (1) $10,627 $11,402 $13,154 $13,521 $48,704 $10,288 $9,353 $10,929 $10,948 $41,518 24 23 17 16 PHARMACEUTICAL 9,238 9,980 11,496 12,039 42,754 8,905 8,178 9,714 9,813 36,610 23 23 17 15 Oncology Keytruda 3,899 4,176 4,534 4,577 17,186 3,284 3,388 3,715 3,993 14,380 15 16 20 18 Alliance Revenue – Lynparza (2) 228 248 246 268 989 145 178 196 206 725 30 33 36 35 Alliance Revenue – Lenvima (2) 130 181 188 206 704 128 151 142 158 580 30 31 21 20 Vaccines (3) Gardasil / Gardasil 9 917 1,234 1,993 1,528 5,673 1,097 656 1,187 998 3,938 53 50 44 39 ProQuad / M-M-R II / Varivax 449 516 661 509 2,135 435 378 576 488 1,878 4 4 14 13 Pneumovax 23 171 152 277 292 893 256 117 375 339 1,087 -14 -13 -18 -19 RotaTeq 158 208 227 213 807 222 168 210 196 797 9 8 1 - Vaqta 34 56 48 41 179 60 28 51 31 170 31 28 5 3 Hospital Acute Care Bridion 340 387 369 436 1,532 299 224 320 355 1,198 23 24 28 27 Prevymis 82 93 96 100 370 60 63 77 80 281 25 27 32 30 Noxafil 67 66 64 62 259 94 73 79 82 329 -25 -24 -21 -23 Primaxin 65 60 70 65 259 51 64 74 62 251 5 2 3 -3 Cancidas 57 54 56 45 212 55 43 50 65 213 -31 -32 - -4 Invanz 57 48 53 45 202 64 43 51 53 211 -15 -15 -4 -6 Zerbaxa (8) (1) (2) 10 (1) 37 32 43 19 130 -47 -47 -101 -101 Immunology Simponi 214 202 203 206 825 215 191 209 223 838 -8 -6 -2 -6 Remicade 85 75 73 67 299 88 73 82 88 330 -24 -22 -9 -12 Neuroscience Belsomra 79 78 81 80 318 79 84 81 83 327 -4 2 -3 -1 Virology Molnupiravir 952 952 * * * * Isentress / Isentress HD 209 192 189 178 769 245 196 205 211 857 -15 -15 -10 -11 Cardiovascular Alliance Revenue - Adempas/Verquvo (4) 74 74 100 94 342 53 79 83 65 281 45 45 22 22 Adempas (5) 55 74 59 63 252 56 57 55 53 220 19 24 14 11 Diabetes (6) Januvia 809 784 852 878 3,324 774 854 821 857 3,306 3 3 1 -1 Janumet 486 477 487 514 1,964 503 490 506 472 1,971 9 10 0 -3 Other Pharmaceutical (7) 581 546 572 610 2,310 605 548 526 636 2,312 -4 -4 0 -1 ANIMAL HEALTH 1,418 1,472 1,417 1,261 5,568 1,214 1,101 1,220 1,168 4,703 8 8 18 16 Livestock 819 821 864 791 3,295 739 648 758 794 2,939 - - 12 10 Companion Animals 599 651 553 470 2,273 475 453 462 374 1,764 26 26 29 26 Other Revenues (8) (29) (50) 241 221 382 169 74 (5) (33) 205 * * 86 176 * 200% or greater 2021 2020 4Q Full Year MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3 (6) Total Diabetes sales were $1,363 million, $1,330 million, $1,417 million, and $1,475 million in the first, second, third, and fourth quarter of 2021, respectively, and $1,353 million, $1,418 million, $1,405 million and $1,412 million in the first, second, third and fourth quarters of 2020, respectively. (7) Includes Pharmaceutical products not individually shown above. (8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues in the first and third quarter of 2021 include $50 million and $135 million, respectively, related to the receipt of milestone payments for an out-licensed product. Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (3) Total Vaccines sales were $1,809 million, $2,293 million, $3,315 million, and $2,715 million in the first, second, third, and fourth quarter of 2021, respectively, and $2,155 million, $1,418 million, $2,521 million and $2,163 million in the first, second, third and fourth quarters of 2020, respectively. (4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (5) Net product sales in Merck's marketing territories. 5 -- 6 of 10 -- 4Q 2021 4Q 2020 % Change 4Q 2021 4Q 2020 % Change 4Q 2021 4Q 2020 % Change TOTAL SALES (1) $13,521 $10,948 24 $6,259 $5,288 18 $7,262 $5,660 28 PHARMACEUTICAL 12,039 9,813 23 5,790 4,903 18 6,249 4,910 27 Oncology Keytruda 4,577 3,993 15 2,657 2,246 18 1,920 1,747 10 Alliance Revenue - Lynparza (2) 268 206 30 144 120 20 123 85 44 Alliance Revenue - Lenvima (2) 206 158 30 131 90 46 75 69 10 Vaccines (3) Gardasil / Gardasil 9 1,528 998 53 275 546 -50 1,253 452 177 ProQuad / M-M-R II / Varivax 509 488 4 374 345 8 135 144 -6 Pneumovax 23 292 339 -14 193 249 -22 99 90 10 RotaTeq 213 196 9 109 131 -17 105 65 61 Vaqta 41 31 31 20 25 -19 21 7 * Hospital Acute Care Bridion 436 355 23 218 172 27 218 183 19 Prevymis 100 80 25 42 32 30 58 48 21 Noxafil 62 82 -25 11 15 -25 50 67 -25 Primaxin 65 62 5 1 * 64 62 4 Cancidas 45 65 -31 5 -98 45 60 -25 Invanz 45 53 -15 (3) 2 * 48 50 -5 Zerbaxa 10 19 -47 9 17 -44 1 2 -68 Immunology Simponi 206 223 -8 206 223 -8 Remicade 67 88 -24 67 88 -24 Neuroscience Belsomra 80 83 -4 22 14 58 58 69 -16 Virology Molnupiravir 952 * 632 * 320 * Isentress / Isentress HD 178 211 -15 72 83 -12 106 128 -17 Cardiovascular Alliance Revenue - Adempas/Verquvo (4) 94 65 45 90 58 55 4 7 -42 Adempas (5) 63 53 19 0 - 63 53 19 Diabetes (6) Januvia 878 857 3 407 360 13 472 497 -5 Janumet 514 472 9 123 115 7 391 356 10 Other Pharmaceutical (7) 610 636 -4 263 278 -5 347 358 -3 ANIMAL HEALTH 1,261 1,168 8 395 361 10 866 807 7 Livestock 791 794 158 165 -4 633 629 1 Companion Animals 470 374 26 237 196 21 233 178 31 Other Revenues (8) 221 (33) * 74 24 * 147 (57) * * 200% or greater Sum of U.S. plus international may not equal global due to rounding. (3) Total Vaccines sales were $2,715 million in the fourth quarter of 2021 and $2,163 million in the fourth quarter of 2020. MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS FOURTH QUARTER 2021 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3a Global U.S. International (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (5) Net product sales in Merck's marketing territories. (6) Total Diabetes sales were $1,475 million in the fourth quarter of 2021 and $1,412 million in the fourth quarter of 2020. (7) Includes Pharmaceutical products not individually shown above. (8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. 6 -- 7 of 10 -- Full Year 2021 Full Year 2020 % Change Full Year 2021 Full Year 2020 % Change Full Year 2021 Full Year 2020 % Change TOTAL SALES (1) $48,704 $41,518 17 $22,425 $19,588 14 $26,279 $21,930 20 PHARMACEUTICAL 42,754 36,610 17 20,401 18,010 13 22,353 18,600 20 Oncology Keytruda 17,186 14,380 20 9,765 8,352 17 7,421 6,028 23 Alliance Revenue - Lynparza (2) 989 725 36 515 417 24 473 308 54 Alliance Revenue - Lenvima (2) 704 580 21 417 359 16 287 220 30 Vaccines (3) Gardasil / Gardasil 9 5,673 3,938 44 1,881 1,755 7 3,792 2,184 74 ProQuad / M-M-R II / Varivax 2,135 1,878 14 1,629 1,378 18 506 500 1 Pneumovax 23 893 1,087 -18 547 727 -25 346 359 -4 RotaTeq 807 797 1 473 486 -3 334 311 7 Vaqta 179 170 5 100 103 -3 79 67 18 Hospital Acute Care Bridion 1,532 1,198 28 762 583 31 770 615 25 Prevymis 370 281 32 153 119 28 218 162 35 Noxafil 259 329 -21 60 42 42 199 287 -30 Primaxin 259 251 3 2 2 -36 258 248 4 Cancidas 212 213 4 7 -42 208 207 1 Invanz 202 211 -4 (5) 9 -157 207 202 3 Zerbaxa (1) 130 -101 4 74 -94 (5) 56 -110 Immunology Simponi 825 838 -2 825 838 -2 Remicade 299 330 -9 299 330 -9 Neuroscience Belsomra 318 327 -3 78 81 -4 241 247 -2 Virology Molnupiravir 952 * 632 * 320 * Isentress / Isentress HD 769 857 -10 294 326 -10 474 531 -11 Cardiovascular Alliance Revenue - Adempas/Verquvo (4) 342 281 22 312 259 21 30 22 35 Adempas (5) 252 220 14 0 - 252 220 14 Diabetes (6) Januvia 3,324 3,306 1 1,404 1,470 -4 1,920 1,836 5 Janumet 1,964 1,971 - 367 477 -23 1,597 1,494 7 Other Pharmaceutical (7) 2,310 2,312 - 1,007 984 2 1,302 1,328 -2 ANIMAL HEALTH 5,568 4,703 18 1,758 1,484 18 3,810 3,219 18 Livestock 3,295 2,939 12 667 612 9 2,628 2,327 13 Companion Animals 2,273 1,764 29 1,091 872 25 1,182 892 32 Other Revenues (8) 382 205 86 266 94 184 116 111 4 * 200% or greater Sum of U.S. plus international may not equal global due to rounding. (3) Total Vaccines sales were $10,132 million and $8,258 million on a global basis for December YTD 2021 and 2020, respectively. MERCK & CO., INC. FRANCHISE / KEY PRODUCT SALES - CONTINUING OPERATIONS FULL YEAR 2021 (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3b Global U.S. International (1) Only select products are shown. (2) Alliance Revenue represents Merck’s share of profits, which are product sales net of cost of sales and commercialization costs. (4) Alliance Revenue represents Merck's share of profits from sales in Bayer's marketing territories, which are product sales net of cost of sales and commercialization costs. (5) Net product sales in Merck's marketing territories. (6) Total Diabetes sales were $5,584 million and $5,588 million on a global basis for December YTD 2021 and 2020, respectively. (7) Includes Pharmaceutical products not individually shown above. (8) Other Revenues are comprised primarily of third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. Other Revenues for December YTD include $185 million related to the receipt of milestone payments for an out-licensed product. 7 -- 8 of 10 -- TOTAL PHARMACEUTICAL $9,238 $9,980 $11,496 $12,039 $42,754 $8,905 $8,178 $9,714 $9,813 $36,610 23 17 United States 4,294 4,647 5,670 5,790 20,401 4,308 3,958 4,842 4,903 18,010 18 13 % Pharmaceutical Sales 46.5% 46.6% 49.3% 48.1% 47.7% 48.4% 48.4% 49.8% 50.0% 49.2% Europe (1) 2,276 2,404 2,445 2,655 9,780 2,116 1,855 2,171 2,314 8,455 15 16 % Pharmaceutical Sales 24.6% 24.1% 21.3% 22.1% 22.9% 23.8% 22.7% 22.3% 23.6% 23.1% China 688 944 1,278 1,352 4,262 628 600 764 670 2,661 102 60 % Pharmaceutical Sales 7.4% 9.5% 11.1% 11.2% 10.0% 7.1% 7.3% 7.9% 6.8% 7.3% Japan 607 637 614 771 2,629 561 601 648 704 2,514 10 5 % Pharmaceutical Sales 6.6% 6.4% 5.3% 6.4% 6.1% 6.3% 7.3% 6.7% 7.2% 6.9% Asia Pacific (other than China and Japan) 437 442 450 488 1,817 411 377 411 414 1,614 18 13 % Pharmaceutical Sales 4.7% 4.4% 3.9% 4.1% 4.2% 4.6% 4.6% 4.2% 4.2% 4.4% Latin America 353 379 434 421 1,587 314 312 372 371 1,369 13 16 % Pharmaceutical Sales 3.8% 3.8% 3.8% 3.5% 3.7% 3.5% 3.8% 3.8% 3.8% 3.7% Eastern Europe/Middle East/Africa 357 318 362 278 1,315 353 309 289 251 1,199 11 10 % Pharmaceutical Sales 3.9% 3.2% 3.1% 2.3% 3.1% 4.0% 3.8% 3.0% 2.6% 3.3% Canada 160 157 164 167 650 159 121 169 149 599 12 9 % Pharmaceutical Sales 1.7% 1.6% 1.4% 1.4% 1.5% 1.8% 1.5% 1.7% 1.5% 1.6% Other 66 52 79 117 313 55 45 48 37 189 216 66 % Pharmaceutical Sales 0.8% 0.4% 0.8% 0.9% 0.8% 0.5% 0.6% 0.6% 0.3% 0.5% 2021 2020 % Change MERCK & CO., INC. PHARMACEUTICAL GEOGRAPHIC SALES - CONTINUING OPERATIONS (AMOUNTS IN MILLIONS) (UNAUDITED) Table 3c Full Year Sum of quarterly amounts may not equal year-to-date amounts due to rounding. (1) Europe represents all European Union countries, the European Union accession markets and the United Kingdom. 2Q 3Q 4Q Full Year 4Q 1Q 2Q 3Q 4Q Full Year 1Q 8 -- 9 of 10 -- OTHER (INCOME) EXPENSE, NET 4Q21 4Q20 Full Year 2021 Full Year 2020 Interest income (9) $ (11) $ (36) $ (59) $ Interest expense 208 206 806 831 Exchange losses 95 56 297 145 Income from investments in equity securities, net (1) (403) (375) (1,940) (1,338) Net periodic defined benefit plan cost (credit) other than service cost (53) (80) (212) (339) Other, net (171) (49) (256) (130) Total (333) $ (253) $ (1,341) $ (890) $ (1) Includes net realized and unrealized gains and losses from investments in equity securities either owned directly or through ownership interests in investment funds. Unrealized gains and losses from investments that are directly owned are determined at the end of the reporting period, while ownership interests in investment funds are accounted for on a one quarter lag. MERCK & CO., INC. OTHER (INCOME) EXPENSE, NET - GAAP (AMOUNTS IN MILLIONS) (UNAUDITED) Table 4 9 -- 10 of 10 --